Pages that link to "Q37995869"
Jump to navigation
Jump to search
The following pages link to Isabelle Ray-Coquard (Q37995869):
Displayed 50 items.
- Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Q24240202) (← links)
- Dualistic classification of epithelial ovarian cancer: Is it clinically relevant? (Q26768502) (← links)
- Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas (Q27851824) (← links)
- Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. (Q27851999) (← links)
- Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing (Q28741842) (← links)
- Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). (Q31018689) (← links)
- Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience (Q31112956) (← links)
- Monogenic and polygenic determinants of sarcoma risk: an international genetic study (Q32491318) (← links)
- A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours (Q33274982) (← links)
- High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults (Q33334885) (← links)
- Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis (Q33370331) (← links)
- Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group (Q33376938) (← links)
- Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study (Q33381250) (← links)
- Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma (Q33381641) (← links)
- Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group (Q33383091) (← links)
- Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes (Q33387020) (← links)
- Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Res (Q33389572) (← links)
- New developments in treatment of ovarian carcinoma: focus on trabectedin (Q33393429) (← links)
- Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (Q33402188) (← links)
- Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study (Q33403930) (← links)
- Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy (Q33408040) (← links)
- A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group (Q33409579) (← links)
- Incorporation of pazopanib in maintenance therapy of ovarian cancer (Q33417673) (← links)
- Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial (Q33427744) (← links)
- Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial (Q33442988) (← links)
- Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu (Q33447149) (← links)
- Development and validation of a bedside score to predict early death in cancer of unknown primary patients (Q33489537) (← links)
- Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region (Q33559074) (← links)
- Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer. (Q33600434) (← links)
- Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's) (Q33654843) (← links)
- Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer (Q33749044) (← links)
- A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (Q33817421) (← links)
- Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial (Q33821400) (← links)
- Validation of prognostic scores for survival in cancer patients beyond first-line therapy (Q33846615) (← links)
- Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer (Q33915672) (← links)
- A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region (Q34005890) (← links)
- Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up (Q34023059) (← links)
- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial (Q34083140) (← links)
- Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis (Q34129408) (← links)
- Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions (Q34210983) (← links)
- High-dose chemotherapy in soft tissue sarcomas of adults (Q34518437) (← links)
- Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial (Q34554316) (← links)
- Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool (Q34560283) (← links)
- Recommendations for the management of GIST patients (Q34562308) (← links)
- ET-743: a novel agent with activity in soft tissue sarcomas (Q34562938) (← links)
- Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program (Q34578850) (← links)
- Phyllodes tumor of the breast. (Q34583689) (← links)
- Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure (Q34605376) (← links)
- Pazopanib for the treatment of soft-tissue sarcoma (Q34645938) (← links)
- Recent advances in understanding and managing leiomyosarcomas (Q34670825) (← links)